News

In This Section

Recent Press Releases

March 31, 2017

Vancouver, British Columbia, March 31, 2017 – Novelion Therapeutics Inc. (NASDAQ: NVLN) (TSX: NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced the appointment of Mark Corrigan, M.D. to its board of directors, effective immediately. Dr. Corrigan will serve as a member of the compliance committee.

March 15, 2017
  • Company Reiterates FY 2017 Total Net Product Sales Expected to be
    Between $155 and $165 million
  •  Global Expansion Plans for Metreleptin Opportunity Underway
March 7, 2017

Vancouver, British Columbia & Cambridge, MA, March 7, 2017 – Novelion Therapeutics Inc. (NASDAQ: NVLN) (TSX: NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced that the United States Patent Trial and Appeal Board (PTAB) issued a written decision in an Inter Partes Review proceeding affirming the patentability of all claims on U.S. 7,932,268 and U.S. 8,618,135 lomitapide dosage regimen patents.

Pages